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An analysis of global HIV prevalence among
refugees, asylum seekers, and migrants, using
the US Bureau of the Census databank
W. Shandera
Baylor College of Medicine, Houston, TX, USA
Background: As a risk-factor population for HIV infection,
unsettled populations, in particular, refugees and migrants are
understudied.
Methods & Materials: Using the US Bureau of the Census
database, all studies listed of high qualitywith keywords “refugee,”
“asylum,” “immigrant,’ or “migrant” were collated. From this
cohort, inapplicable and studies were deleted (eg, those listed as
“non-migrants”). The data were analyzed using STATA 11, with
respect to HIV prevalence, median year of collection, sample size,
and age.
Results: There were 645 eligible studies from 40 countries car-
ried out between 1987 and 2015 deemed adequate for analysis.
Most studies were from Asia (70%) or Africa (24%). The overall HIV
prevalence among unsettled populationswas 6.5% (SD 9.8, median,
2.5%).Over the last5years, among446studies, themeanprevalence
was 6.5%. The 151 studies among only females showed a higher
prevalence than those among only males (8.4% vs 6.4%, P =0.43).
The sample size of 95 studies with data ranged from 5 to
930 persons, mean 359 (the mean HIV prevalence for this subset,
11.5%). Studies with a smaller sample size tended to show higher
HIV prevalence (correlation coefﬁcient, -0.52). There was a small
increase in prevalence through time (correlation coefﬁcient, 0.05).
Studies before 2001 had a median prevalence of 7.7% while those
after2001showedamedianprevalenceof6.3%) (P=0.0001,Kruskal
Wallis. Age values were available for only 72 studies, with a mean
prevalence of 10.5%, and slightly increased with age, correlation
coefﬁcient of 0.28. A regression analysis of age, sample size, and
time of study against prevalence had only 24 studies but showed
that only time of study as signiﬁcant (P = 0.009, adjusted R square,
0.57).
Conclusion: These data on globally unsettled populations show
that while studies with small sample size, of females, and of older
age populations show a higher HIV prevalence, the key factor
remains time of study, with a slow increase in HIV prevalence
through the interval analyzed, 1987-2015. With a mean recent
prevalence of 6.5%, it is important that HIV prevention activities
be directed toward unsettled populations, regardless of other risk
factors.
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Mitochondrial dysfunction among HIV-1
infected patients of South India and evaluation
of mitochondrial DNA as a biomarker of
mitochondrial toxicity
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Background: NRTI class of drugs though they cause mitochon-
drial toxicity, owing to their cost is the preferred class of drugs in
resource-limited settings like India, hence there is a greater need to
identify a novel biomarker of mitochondrial toxicity. In this study
mitochondrial dysfunction was estimated from peripheral blood
mononuclear cells (PBMCs) and the utility of mitochondrial DNA
(mtDNA) as a marker of mitochondrial toxicity was evaluated.
Methods & Materials: In this longitudinal observational study,
40HIV -1 infected patients treatedwithNRTI based regimen and 57
HIV-1 infectedARTuntreatedpatientswere followed for 18months
at an interval of 6 months and data were compared with 24 HIV
uninfected controls. Mitochondrial dysfunction was determined
from mtDNA content by real time PCR, mitochondrial membrane
potential damage (total lymphocyte mlow) by ﬂow cytometry
and ND1gene of mtDNA was sequenced.
Results: Among the HIV infected, mitochondrial dysfunction
was more pronounced in the ART untreated than the treated.
mtDNA content and total lymphocyte mlow (p=<0.0001) were
signiﬁcantly different among the HIV infected than the controls.
Out of the 22 mtDNA variants observed in HIV infected individu-
als, 27% were found to be associated with mitochondrial mediated
pathogenic conditions, distibuted in 10% of on ART and in 8%
of ART untreated . mtDNA content was signiﬁcantly(p<0.0001)
reduced in both the HIV infected groups, ART untreated had
83.3(65.56-113) and treated had 92.53(68.64-126.7), than the
controls(127.5(110.6-167.7)) throughout the follow up, however
it did not differ signiﬁcantly among the HIV infected. Analysis of
mtDNA content in relation to the adverse events, though differed
signiﬁcantly at the ﬁrst (p= 0.014) and second visit (p= 0.029) was
increased in the subsequent visits among the patients symptomatic
for toxicity.
Conclusion: Mitochondrial dysfunction is evident among both
the treated and untreated HIV-1 infected patients of South India.
As mtDNA depletion failed to relate consistently with laboratory
adverse events during the complete follow up, measuring mtDNA
